Journal of Clinical Trials, Pathology and Case Studies
Next-generation tumor profiling identified high total mutation burden (TMB) in Lymphoepithelioma-like carcinoma of the urinary bladder (LELCB): A potential rationale for Immunotherapy
Jianli Dong, Molecular Diagnostics Division, Department of Pathology, University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-0743, USA, Tel: (409) 772-4866, E-mail: firstname.lastname@example.org
Wang, J., et al. Next-generation tumor profiling identified high total mutation burden (TMB) in lymphoepithelioma- like carcinoma of the urinary bladder (LELCB): A potential rationale for Immunotherapy. (2017) Clin Trials Pathol Case Stud 2(1): 66- 69.
© 2017 Wang, J. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
KeywordsUrinary bladder cancer (BC); Lymphoepithelioma-like carcinoma of the urinary bladder (LELCB); Next generation sequencing [NGS]; Tumor-infiltrating lymphocytes; Total mutation burden (TMB); Prognosis; Immune checkpoint inhibitors; Immunotherapy
Urinary Bladder Cancer (BC) is a heterogeneous disease with diverse morphologic and clinical manifestations. Lymphoepithelioma-Like Carcinoma of the Urinary Bladder (LELCB) is rare form of BC with no standard therapies exist. Thus, novel therapies based on underlying tumor biology are needed. Molecular profiling can be used to detect mutational load and molecular subtypes of tumors, which may help in predicting a patient’s sensitivity to immunotherapy approaches, such as PD-1/PD-L1 inhibition. Here we present a case of Lymphoepithelioma-Like Carcinoma of the Urinary Bladder (LELCB) in a 67-year-old male who underwent Transurethral Resection of Bladder Tumor (TURBT), pathology revealed muscle-invasive urothelial carcinoma, lymph epithelial type. Next-Generation gene sequencing identified multiple gene alterations, and high Total Mutation Burden (TMB) in tumor specimens, suggesting targeting the PD-1/PD-L1 axis may be a therapeutic option. A further characterization and description of the outcomes of these rare tumors is warranted to help guide physicians and counsel patients.